Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christiane Pott

Showing results (41-50 of 114) with videos related to

Pageof 12
Sort By:
Transplantation|January 12, 2012
Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder RegistryHeiner Zimmermann, Ilske Oschlies, Susanne Fink, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trialChristian W Scholz, Antonello Pinto, Werner Linkesch, et al.
Blood|October 1, 2005
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaMonika Brüggemann, Thorsten Raff, Thomas Flohr, et al.
Leukemia|August 30, 2019
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trialChristiane Pott, Laurie H Sehn, David Belada, et al.
Leukemia & Lymphoma|July 16, 2010
Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conferenceMartin Dreyling, Eva Hoster, Silvia Bea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2013
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1)Anne T Nies, Elke Schaeffeler, Heiko van der Kuip, et al.
British Journal of Haematology|April 1, 2022
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trialGeorg Hess, Andreas Hüttmann, Mathias Witzens-Harig, et al.
Haematologica|June 12, 2025
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma AllianceChristian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, et al.
Blood|May 30, 2015
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphomaMarie-Hélène Delfau-Larue, Wolfram Klapper, Françoise Berger, et al.
Leukemia|September 16, 2024
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trialsMouhamad Khouja, Linmiao Jiang, Karol Pal, et al.
Pageof 12

Showing results (41-50 of 114) with videos related to

Sort By:
Pageof 12
Transplantation|January 12, 2012
Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder RegistryHeiner Zimmermann, Ilske Oschlies, Susanne Fink, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trialChristian W Scholz, Antonello Pinto, Werner Linkesch, et al.
Blood|October 1, 2005
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaMonika Brüggemann, Thorsten Raff, Thomas Flohr, et al.
Leukemia|August 30, 2019
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trialChristiane Pott, Laurie H Sehn, David Belada, et al.
Leukemia & Lymphoma|July 16, 2010
Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conferenceMartin Dreyling, Eva Hoster, Silvia Bea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2013
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1)Anne T Nies, Elke Schaeffeler, Heiko van der Kuip, et al.
British Journal of Haematology|April 1, 2022
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trialGeorg Hess, Andreas Hüttmann, Mathias Witzens-Harig, et al.
Haematologica|June 12, 2025
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma AllianceChristian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, et al.
Blood|May 30, 2015
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphomaMarie-Hélène Delfau-Larue, Wolfram Klapper, Françoise Berger, et al.
Leukemia|September 16, 2024
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trialsMouhamad Khouja, Linmiao Jiang, Karol Pal, et al.
Pageof 12